“One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care-Reference-Cited by-同舟云学术

“One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care

Published:2023-08-22 Issue: Volume: Page:
ISSN:1932-2259
Container-title:Journal of Cancer Survivorship
language:en
Short-container-title:J Cancer Surviv

Author:

Egeler M. D.,Boomstra E.,Rohaan M. W.,Van den Heuvel N. M. J.,Fraterman I.,Delfos M.,van de Poll-Franse L. V.,Borch T. H.,Svane I. M.,Haanen J. B. A. G.,Retèl V. P.,Boekhout A. H.

Publisher

Springer Science and Business Media LLC

Subject

Oncology (nursing),Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11764-023-01452-8.pdf

Reference50 articles.

1. Hodi FS, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. American Society of Clinical Oncology; 2022.

2. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

3. Vanderwalde AM, et al. Abstract CT013: S1616: ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. Cancer Res. 2022;82(12_Supplement):CT013–3.

4. Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, LaVallee T, Ibrahim R, Wolchok J. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022;10(1):e003853. https://doi.org/10.1136/jitc-2021-003853

5. Ascierto PA, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. American Society of Clinical Oncology; 2017.